News

News

1-20 of 3405 results
1 2 3 4 5 Next »

Computational Model Mostly Predicts LAA Closure Device Implantation Characteristics, Small Study Shows

Nov 30, 2022 by
Jason Wermers, CRTonline.org

A computational model predicted the final size of implanted WATCHMAN FLX devices in 72.7% of patients undergoing left atrial appendage closure (LAAC) in a small, single-center, observational study, new results show.

PASCAL, MitraClip Show Similar Safety, Clinical Outcomes in Patients with Moderate MR – German Study

Nov 30, 2022 by
Bailey Salimes, CRTonline.org

Major adverse events (MAE) and procedural success rates were not significantly different between patients who received underwent mitral valve transcatheter edge-to-edge repair (TEER) with the PASCAL or MitraClip devices, a new study shows.

After PCI, Residual Angina More Common in Diffuse vs. Focal CAD – TARGET-FFR Substudy

Nov 30, 2022 by
Ilan Merdler, CRTonline.org

The baseline pattern of coronary artery disease (CAD) can predict the likelihood of angina relief, according to a new study, which showed that residual angina after percutaneous coronary intervention (PCI) is almost twice as common in patients with diffuse disease, whereas patients with a focal disease have greater improvement in angina and quality of life.

Machine Learning Ultrasomics Model Could Provide Expert-Level LV Assessment, Study Suggests

Nov 28, 2022 by
Jason Wermers, CRTonline.org

A machine learning ultrasomics model predicted left ventricular (LV) remodeling, which was significantly associated with major adverse cardiovascular events (MACE) in both cardiac point-of-care ultrasound (POCUS) and using images from a high-end ultrasound system, a new study shows.

Quality of Life, HF Symptoms Improved at 2-Year Post-TMVR Follow-Up – MITRAL Study

Nov 28, 2022 by
Bailey Salimes, CRTonline.org

The use of balloon-expandable aortic transcatheter heart valves might improve symptoms, quality of life and stable prosthesis function in patients with severe mitral annular calcification (MAC), failed annuloplasty ring and bioprosthetic mitral valve (MV) dysfunction at 2-year follow-up, a new study suggests.

Ticagrelor, Prasugrel Have Similar Rates of MI, Death at 1 Year After PCI, Single-Center Data Analysis Shows

Nov 21, 2022 by
Pavan Reddy, CRTonline.org

Ticagrelor and prasugrel have similar rates of myocardial infarction (MI) and death at 1 year after percutaneous coronary intervention (PCI) for either acute coronary syndrome (ACS) or chronic coronary syndrome (CCS), according to a real-world analysis of data from a single center.

DRA Outperforms Conventional RA on RAO, Hematoma, but at Expense of Higher Access-Site Crossovers: Meta-Analysis

Nov 21, 2022 by
Sukhdeep Bhogal, CRTonline.org

Distal radial access (DRA) lowered the risks of radial artery occlusion (RAO) and EASY (Early Discharge After Transradial Stenting of Coronary Arteries) grade ≥II hematoma but was associated with longer duration for radial artery cannulation and sheath insertion, more attempts and a higher rate of access-site crossover compared to conventional radial access (RA), according to the new meta-analysis.

High Platelet Reactivity Associated with Higher All-Cause Death at 1 and 5 Years Post-PCI, Korean Registry Study Shows

Nov 21, 2022 by
Jason Wermers, CRTonline.org

Among patients who underwent percutaneous coronary intervention (PCI) with drug-eluting stents (DES) and who received dual antiplatelet therapy (DAPT) of aspirin and clopidogrel, high platelet reactivity was associated with all-cause mortality and other adverse events at both 1 and 5 years compared to low platelet reactivity, new study results show

Study Suggests Limited Role for Limited Antegrade Subintimal Tracking in CTO PCI

Nov 21, 2022 by
Ilan Merdler, CRTonline.org

Limited antegrade subintimal tracking (LAST) is associated with lower procedural success, suggesting a limited role of LAST in contemporary percutaneous coronary intervention (PCI) for chronic total occlusions (CTO), according to a new study.

HDL-C Level as Predictor of CHD May Be Associated with Race – US Study

Nov 21, 2022 by
Bailey Salimes, CRTonline.org

Low-density lipoprotein cholesterol (LDL-C) and triglycerides were modest risk factors for coronary heart disease (CHD) in Black and white adults, while low high-density lipoprotein cholesterol (HDL-C) predicted CHD risk in white but not Black adults, a new study suggests.

Elevated Lp(a) Shows ‘Similar’ CV Risks to FH: Population Data

Nov 14, 2022 by
Nathan Gray, CRTonline.org

The risk of myocardial infarction (MI) and atherosclerotic cardiovascular disease (ASCVD) associated with an elevated blood level of lipoprotein(a) [Lp(a)] is similar to that associated with familial hypercholesterolemia (FH), according to a new analysis of population data that provides equivalence measures for risk between raised Lp(a), FH, and raised low-density lipoprotein cholesterol (LDL-C).

2 ‘Clinical Likelihood’ Models Found to Improve CAD Risk Prediction Over Pretest Probability, Study Finds

Nov 14, 2022 by
Will Chu, CRTonline.org

Two predictive models that estimate the clinical likelihood of obstructive coronary artery disease (CAD) have been found to improve outcome prediction compared with the basic pretest probability (PTP) model.

Genotype-Based Classification Shows Higher Precision vs. Phenotype-Based for Cardiomyopathy Outcomes

Nov 14, 2022 by
Nathan Gray, CRTonline.org

Genotypic-based classification of cardiomyopathies (CMPs) shows a higher precision in predicting patient outcomes than phenotype-based classification, according to an analysis of new registry data.

Study Links Higher Maternal and Fetal Cardiac Events with SVD of Left-Sided vs. Right-Sided Bioprosthetic Valves

Nov 14, 2022 by
Will Chu, CRTonline.org

A study has found that in a cohort of pregnant women implanted with bioprosthetic valves (BPV), structural valve dysfunction (SVD) of left-sided BPVs was linked to higher rates of adverse pregnancy outcomes compared to right-sided BPVs.

RDN Does Not Significantly Reduce BP at 6 Months vs. Sham Procedure: SPYRAL HTN – ON MED

Nov 07, 2022 by
Pavan Reddy, CRTonline.org

Radiofrequency renal denervation (RDN) did not significantly reduce blood pressure (BP) at 6 months compared to a sham procedure in patients on antihypertensive medications, new study results show.

Botulinum Toxin A Does Not Significantly Reduce Post-Operative AF, Phase 2 NOVA Study Finds

Nov 07, 2022 by
Pavan Reddy, CRTonline.org

Among patients undergoing cardiac surgery, botulinum toxin type A (AGN-151607) did not significantly reduce post-operative atrial fibrillation (POAF) events in the primary analysis of a phase 2 dose-ranging study.

PREVENT-HD: Rivaroxaban Fails to Reduce the Composite Event Endpoint vs. Placebo in Symptomatic COVID-19

Nov 07, 2022 by
Sukhdeep Bhogal, CRTonline.org

In non-hospitalized symptomatic COVID-19 patients at risk for thrombosis, rivaroxaban did not reduce the composite endpoint of venous and arterial thrombotic events, hospitalization and death compared to placebo at 35 days, according to a new randomized trial.

BEST-CLI Trial: Bypass Outperforms Endovascular Therapy in Surgery-Eligible CLTI Patients with Adequate Saphenous Vein

Nov 07, 2022 by
Jason Wermers, CRTonline.org

In patients with chronic limb-threatening ischemia (CLTI) who were eligible for surgery and had an adequate saphenous vein, surgical bypass outperformed endovascular therapy, but there was no difference between the treatment strategies in CLTI patients without an adequate saphenous vein, new trial results show.

ISCHEMIA-EXTEND Shows No Long-Term All-Cause Mortality Difference in Chronic CAD Patients

Nov 06, 2022 by
Ilan Merdler and Jason Wermers, CRTonline.org

Extended follow-up of the ISCHEMIA randomized trial over a median of 5.7 years demonstrated no difference in all-cause mortality between an initial invasive strategy and an initial conservative strategy for patients with chronic coronary disease, and a lower risk of cardiovascular mortality and higher risk of non-cardiovascular mortality for the initial invasive strategy.

Test Stratification Based on CAD Risk Reduces Need for Catheterization vs. Usual Testing in Patients with Chest Pain – PRECISE Trial

Nov 06, 2022 by
Jason Wermers, CRTonline.org

A “precision” strategy of evaluating patients with chest pain for suspected coronary artery disease (CAD) with test deferral for low-risk patients and the use of cardiac computed tomography angiography (CCTA) in elevated-risk patients showed a 70% reduction in the composite of death, non-fatal myocardial infarction (MI) or catheterization without obstructive CAD compared to standard testing at 1 year, new trial results show.

1-20 of 3405 results
1 2 3 4 5 Next »

Open

CRTonline on Facebook

CRTonline on Twitter

Tweets by CRT_meeting

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

CRTonline on Facebook

CRTonline on Twitter

Explore the Site

Stay Connected